The company behind the COVID-19 treatment drug remdesivir and the HIV antiretroviral medication Biktarvy is closing its ...
Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, ...
Fintel on MSN16h
Wolfe Research Initiates Coverage of Bristol-Myers Squibb (BMY) with Peer Perform RecommendationFintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb (NYSE:BMY) with a Peer ...
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...
Fintel on MSN3d
Leerink Partners Upgrades Bristol-Myers Squibb (BMY)Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Bearish flow noted in Bristol Myers (BMY) Squibb with 6,501 puts trading, or 1.1x expected. Most active are Nov-24 59 puts and 11/29 weekly 50 puts, with total volume in those strikes near 3,400 ...
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...
Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (WBAG:BMYS) from Market Perform to Outperform. There are 3,419 funds or institutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback